Alar Pharmaceuticals

6785.TWO

2.65 USD

0.08

+3.11%

Overview

Last close

2.65 usd

Market cap

176.81M usd

52 week high

9.84 usd

52 week low

2.57 usd

Target price

8.96 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

1914.9332

Price/Book Value

2.7794

Enterprise Value

133.52M usd

EV/Revenue

1441.1593

EV/EBITDA

413.1064

Key financials

Revenue TTM

92649.78 usd

Gross Profit TTM

80049.41 usd

EBITDA TTM

-5.20M usd

Earnings per Share

-0.03 usd

Dividend

N/A usd

Total assets

77.04M usd

Net debt

N/A usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.